About

Fibrodysplasia ossificans progressiva (FOP) is an extremely rare genetic disorder where muscles and connective tissues gradually turn into bone, severely restricting movement over time. Garetosmab is an antibody designed to block activin A, a protein that drives this abnormal bone formation. By targeting this key biological signal, the drug may potentially slow the progression of debilitating skeletal immobilization in FOP patients.